Table 3.
HDACis used in combination in hematological malignancies
| Drug | Study | Phase | Disease | NCT | Status |
|---|---|---|---|---|---|
| vorinostat bortezomib | Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma | III | MM | NCT00773747 | R |
| Sorafenib-Vorinostat | Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | I | AML MDS | NCT00875745 | R |
| Vorinostat,Bortezomib | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma | I | MM | NCT00111813 | ANR |
| SAHA + CHOP | SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma | I II | NHL | NCT00787527 | R |
| Lenalidomide, Vorinostat and Dexamethasone | Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL) (LenVoDex) | I II | PTCL | NCT00972842 | R |
| vorinostat bortezomib | Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | II | MM | NCT00773838 | R |
| Vorinostat CyclophosphamideEtoposide, Prednisone, Rituximab | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | II | DLBCL | NCT00667615 | R |
| vorinostat bortezomib | Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin’s Lymphoma | II | DLBCL | NCT00810576 | R |
| Vorinostat + Pegylated Liposomal Doxorubicin | Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas | I II | Lymphoma | NCT00785798 | R |
| Vorinostat and Decitabine | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | I | NHL, AML,ALL CML | NCT00791011 | R |
| AMG 655, Bortezomib, Vorinostat | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | I | NHL, AML,ALL CML | NCT00791011 | R |
| Vorinostat, Azacitidine | Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | II | MDS | NCT00948064 | R |
| Vorinostat,Gemtuzumab,Ozogamicin,Idarubicin Cytarabine | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | II | AML | NCT01039363 | R |
| Vorinostat, Melphalan, Prednisone | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | I II | MM | NCT00857324 | R |
| Bortezomib and Vorinostat | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma | II | NHL | NCT00992446 | R |
| Vorinostat Lenalidomide, Bortezomib Dexamethasone | A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | I | MM | NCT01038388 | R |
| Vorinostat, Niacinamide, Etoposide] | A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred | II | Lymphoid Malignancies | NCT00691210 | R |
| Vorinostat, Idarubicin, Cytarabine | II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | II | MDS AML | NCT00656617 | R |
| Vorinostat and Azacitidine | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | I II | MDS AML | NCT00392353 | R |
| Vorinostat, Gemtuzumab ozogamicin, Azacitidine | Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia | I II | AML | NCT00895934 | R |
| Vorinostat, Cytarabine, and Etoposide | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | I | AML, MDS, MPN | NCT00357305 | R |
| Vorinostat, Decitabine | Phase I Trial of Vorinostat (MK0683, SAHA) in Combination With Decitabine in Patients With AML or MDS. | I | AML MDS | NCT00479232 | ANR |
| Vorinostat, Gemtuzumab ozogamicin, | Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | II | AML | NCT00673153 | R |
| Vorinostat, Bortezomib, Doxorubicin | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma | I | MM | NCT00744354 | R |
| Vorinostat, Cladribine, Rituximab | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma | I II | MCL, CLL, NHL | NCT00764517 | R |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, Etoposide | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Primary Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | I II | Lymphoma | NCT00601718 | R |
| Vorinostat, Rituximab +/- CHT | Vorinostat, Rituximab, and Combination Chemotherapy In Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | I II | DLBCL | NCT00972478 | R |
| Vorinostat, Fludarabine Cyclophosphamide, Rituximab | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | II | B-CLL, SLL | NCT00918723 | R |
| Vorinostat Cytarabine | Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007) | I II | MDS | NCT00776503 | R |
| Vorinostat Rituximab | Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma | II | NHL | NCT00720876 | R |
| Bortezomib Vorinostat | Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | II | MCL DLBCL | NCT00703664 | R |
| Vorinostat Lenalidomide | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma. | I | MM | NCT00729118 | R |
| Vorinostat Lenalidomide Dexamethasone | Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma | I | MM | NCT00642954 | ANR |
| Flavopiridol Vorinostat | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | I | AML CML MDS | NCT00278330 | ANR |
| Bortezomib Vorinostat | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | II | MDS AML | NCT00818649 | ANR |
| Vorinostat bexarotene | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients | I | CTCL | NCT00127101 | R |
| Dasatinib Vorinostat | Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | I | CML ALL | NCT00816283 | R |
| Decitabine, Vorinostat CHT | Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment | II | CML ALL | NCT00882206 | R |
| Vorinostat Bortezomib | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT) | II | NHL | NCT00837174 | R |
| Panobinostat and Everolimus | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | I II | MM NHL HL | NCT00918333 | R |
| Panobinostat Bortezomib Dexamethasone | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | III | MM | NCT01023308 | R |
| Panobinostat | LBH589 Plus | I II | MDS AML | NCT00691 | R |
| Decitabine | Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia | 938 | |||
| Panobinostat Imatinib | LBH589 and Imatinib in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia | I | CML | NCT00686218 | R |
| Panobinostat Bortezomib | Panobinostat/Velcade in Multiple Myeloma | I | MM | NCT00891033 | R |
| Panobinostat Everolimus | Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma | I II | NHL | NCT00967044 | R |
| Bortezomib, Panobinostat | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | II | PTCL | NCT00901147 | R |
| Panobinostat,, bortezomib, dexamethasone | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (PANORAMA II) | II | MM | NCT01083602 | R |
| Panobinostat, Ara-C,Mitoxantrone | A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia | I | AML | NCT01055483 | R |
| Panobinostat 5-Azacytidine | Dose-Finding Study of Panobinostat Given in Combination With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) | I | MDS, CMML, AML | NCT00946647 | R |
| Melphalan Panobinostat | Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma | I II | MM | NCT00743288 | R |
| Panobinostat +/- EPO | BH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS (GEPARD) | II | MDS | NCT01034657 | R |
| Panobinostat Decitabine | LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia | I II | AML MDS | NCT00691938 | R |
| GIVINOSTAT (ITF2357) + hydroxyurea | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) | II | PV JAK2 + | NCT00928707 | R |
| 5 azacytidine - Valproïc acid- Retinoic acid | 5-Azacytidine Valproic Acid and ATRA in AML and High Risk MDS | II | AML MDS | NCT00339196 | R |
| Entinostat Azacitidine | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | I | MDS CMML AML | NCT00101179 | ANR |
| Entinostat, GM-CSF | A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies | II | MDS | NCT00466115 | R |
| Entinostat ± Azacitidine | Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | II | MDS AML CMML | NCT00313586 | R |
| Entinostat, GM-CSF | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | II | AML ALL MDS MPN | NCT00462605 | R |
| Mocetinostat Azacitidine | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | II | AML MDS | NCT00666497 | C |
| Mocetinostat Azacitidine | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | II | NHL HL | NCT00543582 | C |
| Mocetinostat Azacitidine | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | I II | AML MDS | NCT00324220 | R |
| Belinostat Bortezomib | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | II | MM | NCT00431340 | ANR |
| Belinostat Dexametasone | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | II | MM | NCT00131261 | C |
| Belinostat and Azacitidine | PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | I | Hematological neoplasms | NCT00351975 | R |
| Romidepsin Bortezomib Dexametasone | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | I II | MM | NCT00431990 | R |
| Romidepsin Fludarabine Rituximab | R901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin’s Lymphoma | I II | NHL | NCT00079443 | C |
| Cytarabine, all-trans retinoic acid, valproic acid | Combined Therapy With Valproic Acid, All-trans Retinoic Acid (ATRA) and Cytarabine in Human Acute Myelogenous Leukemia (AML) | I II | AML | NCT00995332 | R |
R recruiting, C completed, ANR active, not recruiting; MDS myelodysplastic syndromes, AML acute myelogenous leukemia, T/B-ALL acute lymphoblastic leukemia (T- or B-cell), HD Hodgkin disease, NHL non-Hodgkin lymphoma, DLBL diffuse large B-cell lymphoma, FL follicular lymphoma, CTCL cutaneous T-cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocyte lymphoma, MCL mantle cell lymphoma, PTCL peripheral T-cell lymphoma, CML chronic myelogenous leukemia, MPN myeloproliferative neoplasm, WM Waldenstrom macroglobulinemia, MM multiple myeloma, PV policytemia vera, ET essential thombocytemia, MMM myelofibrosis with myeloid metaplasia